Industrial Sector… industrial facilities
commitment to EHSMS
Neopharma, a pharmaceutical manufacturer having its facility located in ICAD-1, Mussafah, Abu Dhabi was established in 2003. The factory follows global benchmarks in manufacturing technology that include modern hi-tech automation and control mechanisms.
Neopharma was certified against international standards relevant to EHS in 2008. When approached by the Industrial Sector Regulatory Authority (ZonesCorp) for registration to the Abu Dhabi EHS Management System, Neopharma accepted the initiative and worked towards the achievement of the objectives in partnership with the SRA.
Neopharma’s key objective of the EHS program is to improve compliance to applicable EHS regulations and thus reduce and eliminate EHS incidents and losses. Neopharma strives to be the best performing industrial entity in the region by demonstrating excellent and sustainable performance in Environment, Health and Safety Management.
Neopharma EHSMS was approved by the industrial sector regulatory authority in November 2010. The awareness seminars conducted on regular basis benefited Neopharma in improving the EHS System in areas such as Risk Register, Legal Register and EHS performance monitoring and reporting.
Successful implementation of integrated EHSMS has several benefits, among which are:
Ability to identify any failures and solve problems quickly has reduced the safety breakdown time thereby increasing productivity
• Improvement in overall employee health and attendance
• High standard of safe working
• EHSMS has helped value success. Everyone including operators, maintenance technicians, managers and staff value safety and embrace it daily.
• Safety standards, technology innovations, and thorough risk management techniques now make it possible to develop a more proactive approach to health and safety in the work place.
• No non-compliance issued during the independent 3rd party annual EHSMS audit and inspection done by approved auditor in December 2011. In March 2012, Neopharma received a letter of appreciation from Industrial SRA (ZonesCorp) commending the high EHS standards and performance in the facility and its compliance to the approved EHSMS.
Neopharma participates in the Competitiveness Forum Health care & Access to Innovative Medicines in the UAE organised and held under the auspices of Ministry of Health on November 28th and November 29th, 2012.
Nexgen Pharma eyes marketing 100 off-patent drugs in UAE by 2016
Abu Dhabi: Nexgen Pharma, a joint venture between Hetero India and Abu Dhabi-based Neopharma, plans to market off-patent branded generic drugs in various therapeutic segments in the UAE that include gastroenterology, cardiovascular, neurology, antivirals, antiretrovirals, the partners announced in the capital yesterday.
“As an initial investment, both the companies have invested $5 million each, for marketing,” B.R. Shetty, partner and managing director for Nexgen Pharma told reporters at a news conference.
“In the first phase, we will market 21 products in the UAE. In two years time, we plan to market 50 products in the country and by 2016, the plan is to market 100 products,” said Hetero Group Chairman Bandi Parthasaradhi Reddy.
Hetero, a major international supplier has a portfolio of more than 300 products and has been able to market its products in 138 countries across the globe.
Nexgen Pharma will procure the products from Hetero Labs in India. The products are manufactured in world-class facilities of Hetero, approved by the US FDA, WHO, TGA, EU, PMDA and UAE-MoH.
“Hetero’s strength is its vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialisation. Now, with the launch of Nexgen Pharma, we intend to have the leadership in branded generics market,” said Reddy.
Reddy said in time, some of their drugs could also be manufactured by Neopharma, a local pharmaceuticals manufacturing company.
Separately, Shetty said Neopharma is investing a further Dh200 million in expanding its facility located in the Industrial City of Abu Dhabi (ICAD-I), which would take the total investment in the facility to Dh500 million.
Dr. B R Shetty gets featured in the CEO magazine. To view the document
Neopharma participated in the “Optimal Therapy for H.Pylori Infections Conference”, held on October 5th 2012 at Intercontinental Hotel, Abu Dhabi. Neopharma put up a stall to exhibit banners and products.
The purpose of this conference was to review in depth various issues involving H. pylori infection from various perspectives. This meeting brought together renowned faculty of speakers and experts to cover various clinical and analytical aspects & a good number of participants (250-300) doctors and healthcare professionals.
At the end of the Conference a certificate of appreciation was given. The program was accredited by Health Authority – Abu Dhabi for 7 CME credit hours.
It gives us immense pleasure to inform that Dr. B. R. Shetty is the proud recipient of another award ‘Global Indian of the Year (Male) 2012’ at the Pharmaleaders’s 5th Annual Pharmaceutical Leadership Annual Summit & Business Leadership Awards 2012 held at Hotel Hilton, Mumbai on 21 Sept’12. The award was presented by His Excellency, K. Shankaranarayanan , Governor of Maharashtra
Neopharma organizes â€œBlood Donation Campaignâ€â€¦ Neopharma, organized successfully a voluntary blood donation campaign in collaboration with the Abu Dhabi Blood Bank on 16th September 2012 in the Company premises.
Donating blood is an act of selflessness. To save the life of a stranger is one of the noblest things you can do with your life. It is a manifestation of love for life. Blood symbolizes life in its very essence.
In surgery and treatments human blood is a prime necessity. It is necessary for us all to know that donating blood does not harm the donor. Every volunteer is first examined by a doctor and only if declared physically fit, will be permitted to give blood. According to the Abu Dhabi Blood Bank, eligible donors can give blood safely three to four times per year.
Dr. B.R. Shetty, MD and CEO, said â€œThe act of blood donation is safe. The equipment used for the donation is sterilized and disposable which makes it impossible to acquire diseases or come to any harm. On the contrary donating blood can have beneficial effects as it activates the donorâ€™s blood production in the bone marrow. As blood cannot be manufactured and stored indefinitely it is essential that people volunteer themselves to donate blood. Be a donor and save a life. Blood donors are quiet heroes. Be a hero. Be a Blood donor.â€
Around 50 units of blood were collected and all the donors expressed their happiness to be a part of this noble cause. The employees with great sense of pride expressed through their participation in the Blood donation campaign, therefore, harmless any by doing so a precious life may be saved.
Neopharma, Abu Dhabiâ€™s leading generic pharmaceutical manufacturing facility inaugurated its dedicated world class research and development centre in Musaffah on September 10th, 2012.
Dr B R Shetty – MD & CEO of Neopharma quoted the Hippocratic Oath as his guiding principle, â€œI will prescribe regimens for the good of my patients according to my ability and my judgments and never do harm to anyone.â€
Sharing his vision, Dr B R Shetty said, â€œThe future of healthcare can be assured by providing hi-tech pharmaceutical products and healthcare services to the UAE community and the neighboring regions.â€
While dedicating the Dr B R Shetty Research Centre to the community, Dr Shetty described the research centre as the cornerstone of innovation in pharmaceutical formulations, new drug delivery systems, nanotechnology and biological products for chronic or life threatening diseases.
Dr B R Shetty described the Research Centre as a pivotal hub for the development of novel drug delivery systems aimed at the treatment of Diabetes mellitus and Cancer. In this attempt neopharma has introduced modified release glyclazide(Glyka MR) & extended release metformin tablets (Neomet XR)for diabetic, Clarithromycin modified release(Resclar MR) tablets in antibiotic segment & Diclofenac sustained release tablets (Neoflam retard).
The research centre has collaborated with the Arkansas University for the development of microfiber nanotechnology for glucose sensors and nanotechnology based microchips for neurodegenerative disorders. In our collaboration with the biotech leader Biocon we have introduced novel nanotech product albumin bound paclitaxel for the treatment of breast cancer.
â€œNeopharma dedicates this world class facility to medical science.â€ Dr Shetty added.
We are glad to inform you that our MD & CEO, Dr. B.R. Shetty was recently the proud recipient of two prestigious awards.
On 20th August 2012, Dr. B.R. Shetty was awarded the Rajiv Gandhi Award for the â€˜Best NRI of the Yearâ€™ at the PEHCHAN- 3rd Rajiv Gandhi Excellence Awards for the year 2011 at a glittering ceremony in New Delhi, India. The Rajiv Gandhi Excellence Awards were instituted in the memory of late Indian Prime Minister Rajiv Gandhi in the year 2010. To reward the outstanding performers in the industry, PEHCHAN, an NGO nurturing the Girl Child and working towards the education of the Girl Child and marriage of poor girls, had instituted these Awards to keep alive, the memory of our beloved late Prime Minister, Shri Rajiv Gandhi . The 3rd edition of Rajiv Gandhi Excellence Awards 2011 is a tribute to his vision of a strong and self-reliant India.
At a glittering ceremony held last night at the Emirates Towers, Dubai, our MD & CEO, Dr. B.R. Shetty was awarded the â€œPowerBrands Hall of Fame Humanitarian Par Excellence Awardâ€. This award is to honour Dr.B.R. Shetty for having transformed the healthcare industry through great focus and compassion and for having carved out a niche for himself with his remarkable strategies and vision.